Scientists from Thomas Jefferson University and the National Institutes of Health come one step closer to understanding the difficulty of treating joint infection. Biofilm formation plays a role.
Two birds with one stone: A novel and broad Ebola vaccine in humans or with specially engineered cows could help researchers develop large quantities of Anti-Ebola serum and protect humans against filoviruses.
The study in the postoperative radiation oncology field to show that molecular signature of patient's tumor can help stratify patients requiring additional treatment.
Thomas Jefferson University joins an international genomic medicine collaborative to help offer the newest innovations in cancer care through clinical trials.
Settling a long-time debate, researchers show that sewing up a C-section skin incision with sutures leads to fewer complications than using surgical staples.
The so called fatty liver disease that long time drinkers develop may extend to the lung in a newly discovered side effect of drinking in rats that researchers are calling fatty lung disease.
Researchers suspect that many cancer vaccines fail because the immune cells that would destroy the tumor are actively suppressed. Now, researchers at Thomas Jefferson University have found that a single cell type may be to blame for the suppression, paving the way to better cancer vaccine design.
Researchers have found a common link between muscle weakness in alcoholics and mitochondrial disease: mitochondria that are unable to self-repair. The research could lead to both a new diagnostics for mitochondrial disease and a new drug target.
A derivative of vitamin A, known as retinoic acid, found abundantly in sweet potato and carrots, helps turn pre-cancer cells back to normal healthy breast cells, which may help explain why some clinical studies have been unable to see a benefit of vitamin A on cancer: the vitamin doesn’t appear to change the course of full-blown cancer, only pre-cancerous cells, and only works at a very narrow dose.
Combining radiation with immnotherapy can boost cancer killing. Now a team from Thomas Jefferson University has shown that the boost works best when the therapies are sequenced correctly.
Genomic testing that determines the molecular subtype of a woman’s breast cancer provides a more precise prognosis and valuable guidance about the most effective avenue of treatment.
Thomas Jefferson University is developing a single dose rabies and contraceptive vaccine to reduce the infection's human mortality rates worldwide as part of their Grand Challenges Explorations award, an initiative funded by the Bill & Melinda Gates Foundation.
The Department of Medicine at Thomas Jefferson University has been named a Comprehensive Hypertension Center by the American Society of Hypertension (ASH). Jefferson is one of only five in the country to earn top recognition for its advanced diagnosis, evaluation and treatment of complex hypertension and associated disorders.
New, regional concussion center will offer top, multidisciplinary concussion care--neurology, opthalmology, psychiatry, etc. through a collaboration of Thomas Jefferson University Hospital, Rothman Institute, and Wills Eye Hospital.
When the pros and cons of prostate cancer treatment are spelled out using an online interactive program, more patients choose active surveillance over therapy.
A hologram-like display of a patient’s organs based on molecular PET/CT images helps surgeons plan surgery by allowing them to see detailed anatomical structure, peel away layers of tissue, and see all sides of a tumor, before entering the operating room to excise it.
A team of Thomas Jefferson University researchers has shown that an HDL receptor found on breast cancer cells may be responsible for making this cancer more aggressive, proposing a new molecular target that could help treat the disease.
Renowned national and international leaders in diabetes prevention, treatment and research will descend on Philadelphia for the Second Annual Diabetes Symposium: New Advances and Innovations, a one-day symposium on advancing patient care at the intersection of diabetes and cardiovascular disease, cancer, sexual health and new this year, physicians and diabetes educators will address the latest advances in managing obesity in the diabetic patient.
The symposium is organized and lead by Serge Jabbour, M.D., director of the Division of Endocrinology, Diabetes Center, and Comprehensive Weight Management Program, and Jeffrey Miller, M.D., clinical director, Division of Endocrinology and Co-director of the Thyroid and Parathyroid Center at Jefferson and will commence on Friday, October 11th from 7:30 a.m. to 5:30 p.m. in the Dorrance H. Hamilton Building on the Thomas Jefferson University campus.
Researchers with Jefferson Orthopedics are using their experience and expertise in post-traumatic joint stiffness to develop treatments that could aid in optimal recovery and restoration of joint function for members of the military who sustain traumatic combat or combat-related injuries.
Jefferson School of Population Health researcher Robert Lieberthal, PhD develops a new way to measure hospital quality - and patient satisfaction plays only a minor role. Relevant to the Patient Protection and Affordable Care Act, which links patient satisfaction to hospital reimbursement.
James C. Krieg, M.D., has joined the Rothman Institute at Jefferson as Chief of Orthopedic Trauma and Fracture Care, and Professor of Orthopedic Surgery at Jefferson Medical College.
Raymond Penn, Ph.D., the new director of the Center for Translational Medicine and Director of Pulmonary Research in the newly established Jefferson-Jane and Leonard Korman Lung Center has been awarded a research grant from the National Heart, Lung, and Blood Institute to identify new therapies for the treatment of asthma.
Jefferson Radiation Oncologist, Nicole Simone, M.D., was recently awarded one of 21 Young Investigator Awards from the Prostate Cancer Foundation (PCF).
The award, in the amount of $225,000, will be used to further her research in caloric restriction to decrease tumor growth and metastases in prostate cancer patients.
Young investigator awards support the most innovative minds in the field of prostate cancer research and are designed to promote long-term careers in prostate cancer research by providing three-year grants for transformational research focused on prostate cancer advances and new treatments to improve patient outcomes.
Thomas Jefferson University Hospital has been named to U.S. News & World Report’s most exclusive and influential list: Best Hospitals 2013-14 Honor Roll. Jefferson’s first-ever honor roll ranking at number 17, places it among an elite group of the nation’s top hospitals, chosen for the breadth and depth of clinical excellence.
Recent studies by researchers at Thomas Jefferson University’s Kimmel Cancer Center have shown a gene known to coordinate initial development of the eye (EYA1) is a powerful breast tumor promoter in mice. The gene EYA1 was also shown to be overexpressed in a genetic breast cancer subtype called luminal B.
Researchers from Thomas Jefferson University’s Kimmel Cancer Center have discovered that decorin, a naturally occurring protein that circulates in the blood, acts as a potent inhibitor of tumor growth modulating the tumor microenvironment.
Research from Thomas Jefferson University is laying the foundation for a genetic test to accurately identify hip dysplasia in newborns so that early intervention can be initiated to promote normal development. Researchers studied four generations of a Utah family affected by developmental dysplasia of the hip (DDH) in most generations to determine the genetics of DDH. Their findings are currently available in the Journal of Bone and Mineralizing Research (JBMR) online.
Patients with cancer that has spread to their bones are often treated with radiation therapy to reduce pain. But if that treatment doesn’t work, or can’t be used again, a second, effective option now exists. Results of a clinical trial on the new therapy, presented by a researcher at Jefferson’s Kimmel Cancer Center, is being presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes ‘s expression — among them mutations, amplifications, substitutions, and translocations — have been found in 14 different advanced solid tumors.